Analyst Price Targets — GSK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 30, 2025 11:27 am | Wan Nurhayati | CFRA | $53.00 | $46.67 | StreetInsider | CFRA Upgrades GlaxoSmithKline (GSK) to Buy |
| April 15, 2025 4:37 pm | Peter Verdult | BNP Paribas | $35.25 | $35.68 | TheFly | GSK initiated with a Neutral at BNP Paribas Exane |
| July 2, 2024 6:21 am | Peter Welford | Jefferies | $53.00 | $38.38 | TheFly | GSK price target raised to $53 from $52.50 at Jefferies |
| April 11, 2024 7:48 am | Vamil Divan | Guggenheim | $36.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
| April 11, 2024 7:48 am | Mark Purcell | Morgan Stanley | $85.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
Latest News for GSK
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary hypertension that its new owner believes can improve on the safety profile of existing therapies in a market forecast to reach $18 billion by 2032. The asset at the centre of the deal is HS235, an activin signalling inhibitor that has completed phase I healthy volunteer…
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary...
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under which GSK will acquire all of the outstanding equity interests in 35Pharma. The acquisition includes HS235, a potential best-in-class investigational…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GSK.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.